Trial intelligence / Profile preview

PI-88 plus Docetaxel in Advanced NSCLC

NCT00097851Phase 2Completed

Sponsor: Cellxpert Biotechnology Corp.
Start: Feb 2004
Modality: Bivalent/Multivalent Binders
Countries: 1

Overview

Phase 2, randomised, open-label trial of Muparfostat in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cellxpert Biotechnology Corp. Primary endpoint: Non-progression rate at 6 months. Started Feb 2004; status: completed.

Drugs

Muparfostat

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on NCT00097851.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00097851.